- Home
- AFRI vs BNR Comparison
AFRI vs BNR Comparison
Compare AFRI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | BNR |
|---|---|---|
| Founded | 1943 | 2014 |
| Country | Gibraltar | China |
| Employees | 600 | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 252.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | AFRI | BNR |
|---|---|---|
| Price | $9.89 | $19.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 30.2K |
| Earning Date | 04-29-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.47 | $2.18 |
| 52 Week High | $11.42 | $41.72 |
Technical Indicators
Market Signals| Indicator | AFRI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 52.92 |
| Support Level | $9.38 | $19.72 |
| Resistance Level | $10.00 | $23.42 |
| Average True Range (ATR) | 0.25 | 1.32 |
| MACD | 0.05 | 0.55 |
| Stochastic Oscillator | 59.59 | 84.59 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.